Group 1 - The company, Jincheng Pharmaceutical, reported that as of October 31, 2025, the total number of shareholders is expected to be 26,613 [1]

Core Viewpoint - Jincheng Pharmaceutical (300233) announced on November 13 that its subsidiary, Jincheng Taier, produces and sells Oseltamivir phosphate raw materials, which are used for the treatment and prevention of H1N1 influenza [1] Group 1 - The company is involved in the production and sales of Oseltamivir phosphate, a key antiviral medication [1] - The end formulation products of Oseltamivir phosphate are specifically indicated for the treatment and prevention of H1N1 influenza [1]

Core Viewpoint - Jincheng Pharmaceutical announced the transfer of production technology and licensing rights for "Progesterone Vaginal Soft Capsules" to Haimeini (Shanghai) Pharmaceutical Technology Co., Ltd. for a total fee of 50 million RMB [2] Group 1 - Jincheng Pharmaceutical's wholly-owned subsidiary, Beijing Jincheng Taier Pharmaceutical Co., Ltd., is involved in the transaction [2] - The product being transferred is "Progesterone Vaginal Soft Capsules" (brand name: Langyigeng Baifen®), for which Jincheng Taier holds the drug approval number [2] - The total transaction fee, including tax, is set at 50 million RMB [2]

Core Viewpoint - Jincheng Pharmaceutical (300233.SZ) announced the transfer of production technology and marketing rights for "Progesterone Vaginal Soft Capsules" to Haimerni (Shanghai) Pharmaceutical Technology Co., Ltd. for a total fee of 50 million yuan, which aligns with Jincheng Tail's product development strategy and aims to optimize its product structure and asset efficiency [1][1][1] Group 1 - Jincheng Tail, a wholly-owned subsidiary of Jincheng Pharmaceutical, holds the drug approval number for "Progesterone Vaginal Soft Capsules" (brand name: Langyigengbaifen®) [1] - The total transaction fee for the transfer of rights is 50 million yuan, including tax [1] - The transfer is expected to enhance Jincheng Tail's asset operation efficiency and further optimize its asset structure [1]

Core Viewpoint - Jincheng Pharmaceutical (300233.SZ) announced the transfer of production technology and marketing rights for "Progesterone Vaginal Soft Capsules" to Haimerni (Shanghai) Pharmaceutical Technology Co., Ltd for a total fee of 50 million yuan, which aligns with Jincheng Tail's product development strategy and aims to optimize its product structure and asset efficiency [1] Group 1 - Jincheng Tail, a wholly-owned subsidiary of Jincheng Pharmaceutical, holds the drug approval number for "Progesterone Vaginal Soft Capsules" (brand name: Langyigengbaifen®) [1] - The total transaction fee for the transfer of rights is 50 million yuan, including tax [1] - The transfer is expected to enhance Jincheng Tail's asset operation efficiency and further optimize its asset structure [1]

Core Viewpoint - Jincheng Pharmaceutical's subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., plans to transfer its rights to the production technology and marketing authorization of "Progesterone Vaginal Soft Capsules" to Haimerni (Shanghai) Pharmaceutical Technology Co., Ltd. for a total fee of RMB 50 million [1] Group 1 - The transfer involves the production technology and marketing rights of "Progesterone Vaginal Soft Capsules" (brand name: Langyigeng Baofen) [1] - The total transaction fee is RMB 50 million, which has been agreed upon by both parties after considering the actual value of the product rights and market conditions [1]

Core Viewpoint - Jincheng Pharmaceutical (300233.SZ) announced the transfer of production technology and market authorization rights for "Progesterone Vaginal Soft Capsules" to Haimerni (Shanghai) Pharmaceutical Technology Co., Ltd for a total fee of RMB 50 million [1] Group 1 - Jincheng Pharmaceutical's wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd, is involved in the transaction [1] - The product being transferred is "Progesterone Vaginal Soft Capsules," marketed under the name "Langyigeng Baofen" [1] - The agreed transfer fee of RMB 50 million has been determined based on the actual value of the product rights and market conditions [1]

Group 1 - The core point of the article is that Jincheng Pharmaceutical announced the convening of its 18th board meeting on November 4, 2025, to discuss the transfer of drug production technology and related rights [1] - For the year 2024, Jincheng Pharmaceutical's revenue composition is entirely from the pharmaceutical manufacturing industry, accounting for 100.0% [1] - As of the report date, Jincheng Pharmaceutical has a market capitalization of 6.7 billion yuan [1]

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山东金城医药集团股份有限公司（以下简称"公司"）第六届董事会第十八 次会议通知于 2025 年 10 月 31 日以邮件通知方式发出。本次董事会会议于 2025 年 11 月 4 日在公司会议室以现场和通讯相结合的方式召开。会议应出席董事 9 名，实际出席会议董事 9 名，其中独立董事王新宇、蔡启孝以及非独立董事李家 全、王辉以通讯方式出席本次会议。独立董事李福利委托独立董事蔡启孝出席本 次会议。 本次会议由董事长赵叶青主持，公司部分高级管理人员列席。会议的召开和 表决程序符合《中华人民共和国公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 证券代码：300233 证券简称：金城医药 公告编号：2025-076 山东金城医药集团股份有限公司 第六届董事会第十八次会议决议公告 表决结果：9 票同意，0 票反对，0 票弃权。 三、备查文件 1、 第六届董事会第十八次会议决议； 2、 《产品权益转让协议》； 3、 《北京金城泰尔制药有限公司拟转让"普罗雌烯阴道用软胶囊生产技术 及上市许 ...

山东金城医药集团股份有限公司（以下简称"公司"）分别于2025年10月23 日、2025年11月4日召开了第六届董事会第十七次会议、第六届董事会第十八次会 议，公司独立董事李福利先生因公务原因连续两次未亲自出席上述董事会会议。 根据《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范 运作（2025年修订）》第3.3.4规定"连续两次未亲自出席董事会会议的，董事应 当作出书面说明并对外披露。"公司独立董事李福利先生就上述情况作出书面说 明如下：公司于2025年10月23日、2025年11月4日分别召开第六届董事会第十七次 会议、第六届董事会第十八次会议，本人因公务原因，连续两次未能亲自出席董 事会会议。本人已委托其他董事代为表决董事会会议审议的相关议案，受托人按 照授权委托书的授权内容进行表决，本人对董事会会议作出的决议均无异议。 特此公告。 山东金城医药集团股份有限公司董事会 山东金城医药集团股份有限公司 关于董事连续两次未亲自出席董事会会议的说明 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 2025年11月5日 证券代码：300233 证券 ...